Theriva Biologics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Theriva Biologics.

Price Target: n/a

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

According to 1 stock analyst, the rating for Theriva Biologics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Apr '25	May '25	Jun '25
Strong Buy	1	0	0
Buy	0	0	0
Hold	0	1	1
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	May 8, 2025
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Maintains $25 → $6	Strong Buy	Maintains	$25 → $6	+1,295.35%	Nov 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 55.14M

Revenue Next Year

n/a

EPS This Year

-5.63

from -19.03

EPS Next Year

-5.90

from -5.63

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	-	-	-	26.24M	55.14M
Revenue Growth	-	-	-	-	110.11%	-	-	-
EPS	-165.13	-47.57	-32.66	-28.48	-19.03	-5.63	-5.90	-4.89
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027
High	-5.80	-6.07	-5.03
Avg	-5.63	-5.90	-4.89
Low	-5.41	-5.66	-4.69

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.